Open Access

Expression of PD‑1, PD‑L1 and PD‑L2 is associated with differentiation status and histological type of endometrial cancer

  • Authors:
    • Zhongfu Mo
    • Jing Liu
    • Qiuyang Zhang
    • Zhiquan Chen
    • Jiandong Mei
    • Lunxu Liu
    • Shijie Yang
    • Huina Li
    • Lifei Zhou
    • Zongbing You
  • View Affiliations

  • Published online on: June 16, 2016     https://doi.org/10.3892/ol.2016.4744
  • Pages: 944-950
  • Copyright: © Mo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Endometrial cancer (EC) is the most frequent gynecological malignancy and a major cause of morbidity and mortality for women worldwide. Programmed cell death protein 1 (PD‑1) and its ligands programmed death ligand 1 (PD‑L1) and programmed death ligand 2 (PD‑L2) have been well studied in lung cancer, melanoma and renal‑cell cancer. However, few studies have been performed in EC. The purpose of the present study was to assess the expression of PD‑1, PD‑L1 and PD‑L2 in 35 human normal endometrial tissue samples and 75 human EC tissue samples using immunohistochemical staining. It was found that 61.3% of ECs were positive for PD‑1 staining, which was almost exclusively found in the tumor‑infiltrating immune cells. By contrast, PD‑1 was not expressed in the tumor cells or normal endometrial tissues. It was also found that 14.3% of normal endometria and 17.3% of EC tissues were positive for PD‑L1 expression, while 20.0% of normal endometrium and 37.3% of EC tissues were positive for PD‑L2 expression; however, there was no statistically significant difference between the normal endometrium and EC tissues. PD‑1 expression in the tumor‑infiltrating immune cells was more frequently found in the moderately and poorly‑differentiated ECs and non‑endometrioid (type II) ECs than in the well‑differentiated ECs and endometrioid (type I) ECs. Similarly, PD‑L1 and PD‑L2 expression in the tumor‑infiltrating immune cells was more frequently found in the moderately and poorly‑differentiated ECs and type II ECs than in the type I ECs. The present findings indicate a possible better outcome for future treatment with anti‑PD‑1 or anti‑PD‑L1 antibody‑based therapies against these subgroups of endometrial cancers with frequent expression of the PD‑1/PD‑L1/PD‑L2 axis.

Introduction

Endometrial cancer (EC) is the most common gynecological malignancy, with almost 200,000 cases diagnosed every year, and is a major cause of morbidity and mortality for women worldwide (1,2). EC has been broadly classified into two types, termed type I and type II, which possess different etiologies and patient survival rates (3). Type I EC includes endometrioid adenocarcinomas that represent 80–90% of EC arising from atypical endometrial hyperplasia with unopposed estrogen exposure (4,5). The remaining 10–20% of EC are classified as type II, including papillary serous EC, clear cell EC and other histological variants. Type II ECs are mostly poorly-differentiated, estrogen-independent and aggressive, with a ~50% recurrence rate and mortality rate of 50–60% of patients with stage I–II disease (6). The majority of EC patients are diagnosed at an early stage and are treated by surgery with favorable outcomes. However, certain women are diagnosed at a late stage or with type II EC, and often suffer from worse outcomes with limited adjuvant treatment options and low survival rates, for example, patients with low-grade (well-differentiated) type I ECs have a 5-year survival rate of ~90%, whereas patients with high-grade (poorly-differentiated) type I ECs have a 5-year survival rate of 45–77% (610). By contrast, patients with type II ECs, including papillary serous and clear cell ECs, have a 5-year survival rate of 35–53% (4,6).

Previous studies have identified certain risk factors for EC, such as nulliparity, early age at menarche, late age at menopause, unopposed estrogen treatment, hereditary non-polyposis colorectal cancer and polycystic ovarian syndrome (11,12). However, EC pathogenesis remains poorly understood. Additional attention has been paid to the tumor microenvironment and mechanisms of immune evasion. For example, programmed cell death protein 1 (PD-1) has emerged as a key player in tumor immune evasion. PD-1 is a member of the B7/cluster of differentiation (CD)28 family, which is an immune check-point receptor expressed on T cells, natural killer cells, monocytes and B cells (1315). The ligands for PD-1, namely, programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2), interact with PD-1 to suppress T cell functions and induce tumor immune evasion (16). PD-L1 is expressed by tumor cells and tumor-infiltrating immune cells, including macrophages, dendritic cells and T cells (17). PD-L1 and PD-L2 mRNAs are found in human heart, placenta, spleen, lymph node and thymus tissues. Additionally, PD-L2 mRNA, but not PD-L1 mRNA, is found in human lung, liver, smooth muscle and pancreas tissues (18). In the tumor microenvironment, the PD-1/PD-L1/PD-L2 immune inhibitory pathway plays a pivotal role in the ability of tumor cells to evade the host's immune system by inhibiting cytotoxic T lymphocyte proliferation, inducing apoptosis of infiltrating T cells, and increasing the amount of regulatory T cells (19,20). Based on the understanding of the immunosuppressive function of the PD-1/PD-L1/PD-L2 axis, multiple clinical trials have demonstrated that antibodies against PD-1 or PD-L1 are effective therapeutics to block immune evasion and induce tumor regression in patients with melanoma, non-small cell lung cancer, and renal-cell cancer (2127). Therefore, the US Food and Drug Administration (FDA) has approved the anti-PD-1 antibodies pembrolizumab (Keytruda®; Merck & Co., Inc., Kenilworth, NJ, USA) (28) and nivolumab (Opdivo®; Bristol-Myers Squibb, Princeton, NJ, USA) (29) for the treatment of patients with unresectable or metastatic melanoma. Nivolumab has also been approved for the treatment of patients with metastatic squamous non-small cell lung cancer, with progression on or after platinum-based chemotherapy (30). The FDA has assigned a priority review designation to pembrolizumab as a treatment for patients with advanced non-small cell lung cancer (31). Since the anti-PD-L1 antibody MPDL3280A (Genentech, Inc., South San Francisco, CA, USA) showed responsive rates of 13–26% in solid tumors, including non-small cell lung cancer (17), the FDA has assigned MPDL3280A a breakthrough therapy designation for the treatment of PD-L1-positive non-small cell lung cancer that has progressed during or subsequent to platinum-based chemotherapy, as well as a targeted therapy for patients with epidermal growth factor receptor-positive or anaplastic lymphoma kinase-positive tumors, pending the outcomes of ongoing phase II and III trials (32).

There have been an extremely limited number of studies on PD-1 and EC (33,34), and neither of the previous two studies has addressed the association between PD-1 expression and clinicopathological characteristics of EC patients. Therefore, the aim of the present study was to assess expression of PD-1, PD-L1 and PD-L2 in EC and to compare the expression of these proteins with clinicopathological characteristics. Immunohistochemical (IHC) staining was performed in 35 normal endometrium tissues and 75 EC tissues. It was found that PD-1 expression was significantly increased in EC than in normal endometrium and that expression of PD-1, PD-L1 and PD-L2 in the tumor-infiltrating immune cells was associated with differentiation status and histological type of EC.

Materials and methods

Human endometrial tissue samples

In total, 35 samples of normal endometrium and 75 samples of ECs that were archived from surgeries performed between January 2012 and December 2014, in the Department of Obstetrics and Gynecology at Shijiazhuang Maternal and Child Health Care Hospital and the Department of Obstetrics and Gynecology at Shijiazhuang First Hospital (Shijiazhuang, Hebei, China) were retrospectively collected. The samples were formalin-fixed and paraffin-embedded tissue blocks and the pathological diagnoses were re-confirmed by a pathologist. The present study was approved by the Institutional Review Boards of Shijiazhuang Maternal and Child Health Care Hospital and Shijiazhuang First Hospital. The procedures to obtain human endometrial tissues were in accordance with the Ethical Principles for Medical Research Involving Human Subjects, as formulated in the World Medical Association Declaration of Helsinki (2008 revision). The clinicopathological characteristics of the patients were summarized in Table I.

Table I.

Clinicopathological characteristics of patients.

Table I.

Clinicopathological characteristics of patients.

CharacteristicsNumber
Normal endometrium35
  Age, mean ± SD (years)45.3±5.6
Endometrial cancer75
  Age, mean ± SD (years)57.3±10.1
  <60 years45
  ≥60 years30
Differentiation
  Well37
  Moderate23
  Poor15
Stage
  I62
  II  4
  III  9
Histological type
  Endometrioid63
  Papillary serous11
  Clear cell  1
Vascular invasion
  Yes  7
  No68

[i] SD, standard deviation.

Immunohistochemistry

Tissue sections (4-µm thick) were baked at 60°C for 60 min, deparaffinized in xylene and rehydrated through graded ethanol solutions to water. The antigens were retrieved by heating the tissue sections in 0.01 M ethylenediaminetetraacetic acid buffer at 95°C for 5 min and then cooling down to room temperature for 20 min. Endogenous peroxidase activity was blocked by 0.3% H2O2 for 5 min. Non-specific binding was blocked with 1.5% normal goat or horse serum (VECTASTAIN Elite ABC kit; Vector Laboratories, Burlingame, CA, USA). The tissue sections were incubated with primary antibodies in a humid chamber at 4°C overnight. Rabbit anti-human PD-L1 polyclonal antibodies (dilution, 1:400; catalog no., ab58810; Abcam, Cambridge, MA, USA), rabbit anti-human PD-L2 polyclonal antibodies (dilution, 1:800; catalog no., SAB3500395-100UG; Sigma-Aldrich, St. Louis, MO, USA), and rabbit anti-human CD279 (PD-1) affinity-purified and validated polyclonal antibodies (dilution, 1:600; catalog no., PIPA520351; Fisher Scientific; Thermo Fisher Scientific, Inc., Waltham, MA, USA) were used as the primary antibodies. Subsequent to being washed 3 times in phosphate-buffered saline, the tissue sections were incubated with goat anti-rabbit polyclonal secondary antibodies (dilution, 1:200; catalog no., PK-6101; VECTASTAIN Elite ABC kit; Vector Laboratories) for 2 h at room temperature. The color was developed using 3,3′-diaminobenzidine substrate kit (Vector Laboratories) following the manufacturer's protocol. The tissue sections were then counterstained with hematoxylin. The tissue sections that had previously stained positively for PD-1, PD-L1 and PD-L2 in a pilot study were used as positive controls and the tissue sections stained with non-immune serum (Vector Laboratories) acted as negative controls. Positive staining for PD-1, PD-L1 and PD-L2 appeared as brown particles at the cytoplasmic membrane or in the cytoplasm. Under microscopy, 5 representative high-power fields (×400 magnification) per tissue section were randomly selected and evaluated by two investigators, who were blinded to the clinicopathological data. An average of the scores obtained by the two examiners was used to represent each case. A two-score system based on a proportion score and an intensity score was used, as previously described by Allred et al (35). The proportion scores indicated the proportion of positive staining: 0, None; 1, less than one-hundredth; 2, one-hundredth to one-tenth; 3, one-tenth to one-third; 4, one-third to two-thirds; and 5, greater than two-thirds. The intensity scores represented the estimated average staining intensity of positive staining: 0, None; 1, weak; 2, intermediate; and 3, strong. The overall scores (Allred scores) were the sum of the proportion score and intensity score of each case (range, 0–8).

Statistical analysis

Statistical analysis was performed using SPSS version 16.0 for Windows (SPSS, Inc., Chicago, IL, USA). Patient age was expressed as mean ± standard deviation. The comparison of clinicopathological characteristics between different groups was performed using the χ2 test. Spearman's correlation coefficient was calculated to reveal the correlation between PD-1 scores and PD-L1 or PD-L2 scores. P<0.05 was considered to indicate a statistically significant difference.

Results

PD-1, PD-L1 and PD-L2 are expressed in endometrial cancer

IHC staining for PD-1, PD-L1 and PD-L2 was performed using 35 normal endometrium tissues and 75 EC tissues. Representative photomicrographs of the stained samples are shown in Fig. 1. Any sample was defined as having positive staining if the Allred score was ≥1 and any sample was defined as having negative staining if the Allred score was 0. It was found that all normal endometrial samples were negative for PD-1 expression, whereas 61.3% of ECs were positive for PD-1 staining (Table II; P<0.001). In total, 14.3% of normal endometrial samples were positive for PD-L1 staining, while 17.3% of ECs were positive for PD-L1 staining (Table II; P=0.687). In addition, 20.0% of normal endometrial samples were positive for PD-L2 staining, while 37.3% of ECs were positive for PD-L2 staining (Table II; P=0.069). It was found that PD-1 was only expressed in the tumor-infiltrating immune cells, but not in the tumor cells (Fig. 1). By contrast, PD-L1 and PD-L2 were expressed in the tumor cells and infiltrating immune cells (Fig. 1).

Table II.

Expression of PD-1, PD-L1 and PD-L2 in normal endometrium and EC.

Table II.

Expression of PD-1, PD-L1 and PD-L2 in normal endometrium and EC.

PD-1PD-L1PD-L2



GroupnPositive, n (%)P-valuePositive, n (%)P-valuePositive, n (%)P-value
Normal350 (0.0)<0.001  5 (14.3)0.687  7 (20.0)0.069
EC7546 (61.3) 13 (17.3) 28 (37.3)

[i] EC, endometrial cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PD-L2, programmed death ligand 2.

PD-1 expression is associated with differentiation status and histological type of EC

As shown in Table III, the rate of positive PD-1 staining was 73.7% in the poorly and moderately-differentiated ECs, which was significantly increased compared with the well-differentiated ECs (48.6%; P=0.026). The rate of positive PD-1 staining was 100% in the non-endometrioid ECs, including 11 papillary serous ECs and 1 clear cell EC, which was significantly increased compared with the endometrioid ECs (54.0%; P=0.006; Table III). However, PD-1 expression was not different among patients with different ages, clinical stages or statuses of vascular invasion in the tumors (Table III).

Table III.

PD-1 expression and clinicopathological characteristics of patients with endometrial cancer.

Table III.

PD-1 expression and clinicopathological characteristics of patients with endometrial cancer.

CharacteristicsnPositive, n (%)P-value
Patients7546 (61.3)
Age
  <60 years4526 (57.8)0.439
  ≥60 years3020 (66.7)
Differentiation
  Well3718 (48.6)0.026
  Poor/moderate3828 (73.7)
Stage
  I6236 (58.1)0.204
  II/III1310 (76.9)
Histological type
  Endometrioid6334 (54.0)0.006
  Non-endometrioid12  12 (100.0)
Vascular invasion
  Yes  7  4 (57.1)1.000
  No6842 (61.8)
PD-L1 expression in the tumor-infiltrating immune cells is associated with the differentiation status and histological type of EC

As shown in Table IV, the rate of positive PD-L1 staining in the tumor-infiltrating immune cells was ~73.7% in the poorly and moderately-differentiated ECs, which was significantly increased compared with the well-differentiated ECs (45.9%; P=0.014). The rate of positive PD-L1 staining in the tumor-infiltrating immune cells was 100% in the non-endometrioid ECs, which was significantly increased compared with in the endometrioid ECs (52.4%; P=0.006; Table IV). However, PD-L1 expression in the tumor-infiltrating immune cells was not different among patients with different ages, clinical stages or statuses of vascular invasion in the tumors (Table IV). In addition, PD-L1 expression in the tumor cells was not significantly different among patients with different ages, differentiation statuses, clinical stages, histological types or statuses of vascular invasion in the tumors (Table IV).

Table IV.

Association between programmed death ligand 1 expression and clinicopathological characteristics of endometrial cancer patients.

Table IV.

Association between programmed death ligand 1 expression and clinicopathological characteristics of endometrial cancer patients.

Tumor cellsImmune cells


CharacteristicsnPositive, n (%)P-valuePositive, n (%)P-value
Patients7513 (17.3)45 (60.0)
Age 0.681 0.149
  <60 years45  7 (15.6) 24 (53.3)
  ≥60 years30  6 (20.0) 21 (70.0)
Differentiation 0.141 0.014
  Well37  4 (10.8) 17 (45.9)
  Poor/moderate38  9 (23.7) 28 (73.7)
Stage 0.315 0.171
  I62  9 (14.5) 35 (56.6)
  II/III13  4 (30.8) 10 (77.0)
Histological type 0.237 0.006
  Endometrioid63  9 (14.3) 33 (52.4)
  Non-endometrioid12  4 (33.3)   12 (100.0)
Vascular invasion 0.764 0.427
  Yes  7  2 (28.6)   3 (42.9)
  No6811 (16.2) 42 (61.8)
PD-L2 expression in the tumor-infiltrating immune cells is associated with the differentiation status and histological type of EC

As shown in Table V, the rate of positive PD-L2 staining in the tumor-infiltrating immune cells was 73.7% in the poorly and moderately-differentiated ECs, which was significantly higher than in the well-differentiated ECs (51.4%; P=0.046). The rate of positive PD-L2 staining in the tumor-infiltrating immune cells was 100% in the non-endometrioid ECs, which was significantly higher than in the endometrioid ECs (55.6%; P=0.003; Table V). However, PD-L2 expression in the tumor-infiltrating immune cells was not significantly different among patients with different ages, clinical stages or statuses of vascular invasion in the tumors (Table V). Additionally, PD-L2 expression in the tumor cells was not significantly different among patients with different ages, differentiation statuses, clinical stages, histological types or statuses of vascular invasion in the tumors (Table V).

Table V.

Association between programmed death ligand 2 expression and clinicopathological characteristics of endometrial cancer patients.

Table V.

Association between programmed death ligand 2 expression and clinicopathological characteristics of endometrial cancer patients.

Tumor cellsImmune cells


CharacteristicsnPositive, n (%)P-valuePositive, n (%)P-value
Patients7528 (37.3)47 (62.7)
Age 0.380 0.119
  <60 years4515 (33.3) 25 (55.6)
  ≥60 years3013 (43.3) 22 (73.3)
Differentiation 0.698 0.046
  Well3713 (35.1) 19 (51.4)
  Poor/moderate3815 (39.5) 28 (73.7)
Stage 1.000 0.393
  I6223 (37.1) 37 (59.7)
  II/III13  5 (38.5) 10 (76.9)
Histological type 0.188 0.003
  Endometrioid6321 (33.3) 35 (55.6)
  Non-endometrioid12  7 (58.3)   12 (100.0)
Vascular invasion 0.095 0.413
  Yes  7  5 (71.4)   3 (60.0)
  No6823 (33.8) 44 (64.7)
PD-1 expression is associated with PD-L1 and PD-L2 expression in the tumor cells and infiltrating immune cells

It was found that the PD-L1 and PD-L2 Allred staining scores were higher in the tumor-infiltrating immune cells than the tumor cells alone (Fig. 2). Since PD-1 was only expressed in the tumor-infiltrating immune cells, Spearman's correlation analysis was performed between PD-1 scores and PD-L1 or PD-L2 scores. It was found that the PD-1 score was positively associated with the PD-L1 or PD-L2 score in the tumor cells and infiltrating immune cells (Fig. 2).

Discussion

The present study found that 61.3% of human ECs stained positive for PD-1, which was almost exclusively found in the tumor-infiltrating immune cells. By contrast, PD-1 was not expressed in the tumor cells or normal endometrial tissues. It was also found that 14.3% of normal endometria and 17.3% of ECs were positive for PD-L1 expression, while 20.0% of normal endometria and 37.3% of ECs were positive for PD-L2 expression, though there was no statistically significant difference between normal endometrium and EC. Vanderstraeten et al (34) reported that PD-1 expression was present in all 15 cases of normal endometria, PD-L1 expression was present in 81% of 16 cases of normal endometria, and PD-L2 expression was present in 47% of 15 cases of normal endometria. In primary ECs, Vanderstraeten et al found that PD-1 expression was present in 100% of 30 cases of ECs, PD-L1 expression was present in 83% of 29 cases of ECs, and PD-L2 expression was present in 40% of 30 cases of ECs. The discrepancy between the present study and the study by Vanderstraeten et al (34) may be due to different antibodies and IHC protocols used. It may also be due to the different EC patients studied. For example, the study by Vanderstraeten et al included 28 cases of papillary serous and clear cell ECs who were compared with 16 cases of endometrioid ECs (34). By contrast, the present study compared 12 cases of papillary serous and clear cell ECs with 63 cases of endometrioid ECs. Therefore, it is expected that Vanderstraeten et al should find more PD-1, PD-L1 and PD-L2-positive cases than the present study, since the present study showed that non-endometrioid ECs were 100% positive for PD-1, PD-L1 and PD-L2 expression, if we did not distinguish between the tumor cells and infiltrating immune cells. In addition, Howitt et al (33) reported that PD-1 was overexpressed in tumor-infiltrating lymphocytes of 81% of polymerase ε-mutated ECs and 28% of microsatellite-instable ECs. In peritumoral lymphocytes, PD-1 was overexpressed in 90% of polymerase ε-mutated ECs and 28% of microsatellite-instable ECs. PD-L1 expression was infrequently noted in the tumor cells, but was common in intraepithelial immune cells and more frequent in polymerase ε-mutated ECs (39%) than in microsatellite-instable ECs (13%; P=0.02) (33). The present study also showed that PD-L1 and PD-L2 expression was less frequently found in the tumor cells than in the tumor-infiltrating immune cells, which is consistent with the findings of Howitt et al (33).

The present study went beyond the previous two studies (33,34) to show the correlation between the expression of PD-1, PD-L1 and PD-L2 and clinicopathological characteristics of ECs. It was shown that PD-1 expression in the tumor-infiltrating immune cells was more frequently found in the moderately and poorly-differentiated ECs and non-endometrioid (type II) ECs than in the well-differentiated ECs and endometrioid (type I) ECs. Similarly, it was shown that PD-L1 and PD-L2 expression in the tumor-infiltrating immune cells was more frequently found in the moderately and poorly-differentiated ECs and non-endometrioid (type II) ECs than in the well-differentiated ECs and endometrioid (type I) ECs. It is known that moderately and poorly-differentiated ECs and type II ECs have a lower 5-year survival rate than the well-differentiated ECs and type I ECs (610). Therefore, the present findings suggest that more frequent expression of PD-1, PD-L1 and PD-L2 in the moderately and poorly-differentiated ECs and type II ECs may cause immunosuppression to favor tumor growth, thus negatively affecting the patient's survival. Future studies may address whether expression of PD-1, PD-L1 and PD-L2 may be used as an independent predictor of patient survival, once the follow-up data for the present patients are available. The follow-up data are not available at this time due to the short period subsequent to inclusion of the cases. By contrast, it is reasonable to speculate that the moderately and poorly-differentiated ECs and type II ECs may be more sensitive to anti-PD-1 or anti-PD-L1 antibodies-based therapies, since it has been demonstrated in clinical trials that PD-L1-positive tumors tend to be more responsive to anti-PD-1 or anti-PD-L1 therapies (17,26).

In summary, the present study demonstrates that the expression of PD-1, PD-L1 and PD-L2 is associated with moderately and poorly-differentiated endometrial cancer and type II endometrial cancer. Frequent expression of the PD-1/PD-L1/PD-L2 axis in these subgroups of endometrial cancers may be potentially correlated with their aggressive progression and poor patient survival. The present findings indicate a possible improved outcome for future treatment with Keytruda and Opdivo in these subgroups of endometrial cancers with frequent expression of the PD-1/PD-L1/PD-L2 axis.

Acknowledgements

Z.Y. was supported partially by National Institutes of Health (grant nos. R01CA174714 and P20GM103518), Department of Defense (grant nos. W81XWH-14-1-0050, W81XWH-14-1-0149, W81XWH-14-1-0458 and W81XWH-15-1-0444), Developmental Fund of Tulane Cancer Center, Louisiana Cancer Research Consortium Fund, and Tulane's Institute of Integrated Engineering for Health and Medicine. Z.M., Z.C. and S.Y. were supported by the Service Center for Experts and Scholars of Hebei Province, China to pursue research in the USA. L.L. was partially supported by National Natural Science Foundation of China (grant nos. NSFC 81172236 and NSFC 81372505) and Key Science and Technology Program of Sichuan Province, China (grant no. 2013SZ0005). J.M. was a visiting scholar at Tulane University School of Medicine sponsored by the China Scholarship Council (grant no. 201406240145).

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Bray F, Loos AH, Oostindier M and Weiderpass E: Geographic and temporal variations in cancer of the corpus uteri: Incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer. 117:123–131. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI

4 

Mendivil A, Schuler KM and Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: A review of selected histological subtypes. Cancer Control. 16:46–52. 2009.PubMed/NCBI

5 

Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, et al: Stage I, grade III endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 116:10–14. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC and Greer BE: Uterine papillary serous carcinoma: Patterns of metastatic spread. Gynecol Oncol. 54:264–268. 1994. View Article : Google Scholar : PubMed/NCBI

7 

Hidaka T, Kato K, Yonezawa R, Shima T, Nakashima A, Nagira K, Nakamura T and Saito S: Omission of lymphadenectomy is possible for low-risk corpus cancer. Eur J Surg Oncol. 33:86–90. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, Duska LR and Oliva E: Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: Similar outcomes belie distinctive biologic differences. Am J Surg Pathol. 31:979–987. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Petignat P, Usel M, Gauthier P, Popowski Y, Pelte MF, Bouchardy C and Verkooijen HM: Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. Eur J Gynaecol Oncol. 29:57–60. 2008.PubMed/NCBI

10 

Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS and Chan JK: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade III endometrioid corpus cancers. Br J Cancer. 94:642–646. 2006.PubMed/NCBI

11 

Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lannom L and Hoover RN: Reproductive, menstrual, and medical risk factors for endometrial cancer: Results from a case-control study. Am J Obstet Gynecol. 167:1317–1325. 1992. View Article : Google Scholar : PubMed/NCBI

12 

McPherson CP, Sellers TA, Potter JD, Bostick RM and Folsom AR: Reproductive factors and risk of endometrial cancer. The iowa women's health study. Am J Epidemiol. 143:1195–1202. 1996. View Article : Google Scholar : PubMed/NCBI

13 

Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of pd-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992.PubMed/NCBI

14 

Keir ME, Butte MJ, Freeman GJ and Sharpe AH: Pd-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Sharpe AH and Freeman GJ: The b7-cd28 superfamily. Nat Rev Immunol. 2:116–126. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Blank C, Gajewski TF and Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol Immunother. 54:307–314. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2:261–268. 2001. View Article : Google Scholar : PubMed/NCBI

19 

Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 443:350–354. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Okazaki T and Honjo T: PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol. 19:813–824. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, et al: Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 19:462–468. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI

28 

FDA News Release: FDA approves Keytruda for advanced melanoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htmAccessed. January. 2016

29 

FDA News Release: FDA approves Opdivo to treat advanced form of kidney cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htmAccessed. January. 2016

30 

Nivolumab (Opdivo). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436566.htmAccessed. January. 2016

31 

http://www.onclive.com/web-exclusives/fda-grants-priority-review-to-pembrolizumab-in-lung-cancerAccessed. January. 2016

32 

Cha E, Wallin J and Kowanetz M: PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol. 42:484–487. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, et al: Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1:1319–1323. 2015. View Article : Google Scholar : PubMed/NCBI

34 

Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S and Amant F: Mapping the immunosuppressive environment in uterine tumors: Implications for immunotherapy. Cancer Immunol Immunother. 63:545–557. 2014. View Article : Google Scholar : PubMed/NCBI

35 

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK and McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 85:200–206. 1993. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August-2016
Volume 12 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mo Z, Liu J, Zhang Q, Chen Z, Mei J, Liu L, Yang S, Li H, Zhou L, You Z, You Z, et al: Expression of PD‑1, PD‑L1 and PD‑L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett 12: 944-950, 2016.
APA
Mo, Z., Liu, J., Zhang, Q., Chen, Z., Mei, J., Liu, L. ... You, Z. (2016). Expression of PD‑1, PD‑L1 and PD‑L2 is associated with differentiation status and histological type of endometrial cancer. Oncology Letters, 12, 944-950. https://doi.org/10.3892/ol.2016.4744
MLA
Mo, Z., Liu, J., Zhang, Q., Chen, Z., Mei, J., Liu, L., Yang, S., Li, H., Zhou, L., You, Z."Expression of PD‑1, PD‑L1 and PD‑L2 is associated with differentiation status and histological type of endometrial cancer". Oncology Letters 12.2 (2016): 944-950.
Chicago
Mo, Z., Liu, J., Zhang, Q., Chen, Z., Mei, J., Liu, L., Yang, S., Li, H., Zhou, L., You, Z."Expression of PD‑1, PD‑L1 and PD‑L2 is associated with differentiation status and histological type of endometrial cancer". Oncology Letters 12, no. 2 (2016): 944-950. https://doi.org/10.3892/ol.2016.4744